20.1
Pulmonale Hypertonie: Klassifikation und Pathogenese
Pulmonale Hypertonie (PH) ist ein schwerwiegender Gesundheitszustand, bei dem der mittlere pulmonal-arterielle Druck auf 25 mmHg oder mehr ansteigt, s…
Pulmonale Hypertonie (PH) bezeichnet den mittleren Lungenarteriendruck im Ruhezustand von 25 mm Hg oder höher.
Die pulmonale Hypertonie kann aufgrund einer Linksherzerkrankung, Lungenerkrankungen oder Hypoxie, einer chronischen thromboembolischen PH, einer PH mit unklaren multifaktoriellen Mechanismen und einer pulmonalen arteriellen Hypertonie oder PAH in PH eingeteilt werden.
PAH ist eine seltene, tödliche Erkrankung, die durch vaskuläre Veränderungen in kleinen Arterien und Arteriolen gekennzeichnet ist, die zu einem erhöhten pulmonalarteriellen Druck und Gefäßwiderstand führen.
Zu den Schlüsselmechanismen bei PAH gehören der pulmonale Gefäßumbau, die anhaltende pulmonale Vasokonstriktion, die in situ Thrombose und die Versteifung der pulmonalen Gefäßwand.
Verminderte vasoaktive Mediatoren wie Prostacyclin und erhöhte Vasokonstriktoren wie ET-1 tragen zur Vasokonstriktion bei.
Zu den Symptomen der PH gehören Dyspnoe, Müdigkeit, Brustschmerzen und Synkopen.
Zu den potenziellen therapeutischen Optionen für PH gehören cGMP-Signalstimulatoren, Stickstoffmonoxidtherapien, Membranrezeptorantagonisten und -agonisten sowie Ionenkanalblocker.
View the full transcript and gain access to JoVE Core videos
Q1: What is the diagnostic threshold for pulmonary hypertension?
Pulmonary hypertension is diagnosed when the resting mean pulmonary arterial pressure reaches 25 mm Hg or higher. This elevated pressure in the blood vessels transporting blood from the heart to the lungs can cause significant symptoms and lead to right heart failure. The condition affects overall quality of life and requires prompt medical evaluation.
Q2: How is pulmonary arterial hypertension different from other types of pulmonary hypertension?
Pulmonary arterial hypertension (PAH) is a rare, fatal form characterized by vascular changes in small arteries and arterioles, causing elevated pulmonary arterial pressure and vascular resistance. Unlike other PH types linked to left heart disease, lung disease, or blood clots, PAH involves distinct mechanisms including pulmonary vascular remodeling, sustained vasoconstriction, in situ thrombosis, and vascular wall stiffening.
Q3: What causes pulmonary vasoconstriction in pulmonary arterial hypertension?
Pulmonary vasoconstriction in PAH results from imbalanced vasoactive mediators. Decreased vasodilators like nitric oxide and prostacyclin reduce vessel widening, while increased vasoconstrictors like endothelin-1 (ET-1) promote narrowing and smooth muscle cell proliferation. This mediator imbalance drives sustained constriction and worsens vascular resistance.
Q4: What are the main symptoms of pulmonary hypertension?
Pulmonary hypertension symptoms include dyspnea (shortness of breath), fatigue, chest pain, and syncope (fainting). These symptoms typically worsen over time, progressively limiting patients' ability to perform routine activities. Early recognition of these signs is important for timely diagnosis and intervention.
Q5: What therapeutic mechanisms are used to treat pulmonary arterial hypertension?
Treatment for pulmonary arterial hypertension employs multiple mechanisms: cGMP signaling stimulators enhance vasodilation, nitric oxide therapies promote vessel widening, membrane receptor antagonists and agonists modulate vasoactive pathways, and ion channel blockers reduce vascular resistance. Treatment choice depends on PAH severity and patient health status.
Q6: How do the five classifications of pulmonary hypertension differ?
The five PH classifications are: PH due to left heart disease, PH from lung diseases or hypoxia, chronic thromboembolic PH (caused by blood clots), PH with unclear multifactorial mechanisms, and pulmonary arterial hypertension (PAH). Each classification relates to different underlying causes, treatment approaches, and prognoses, guiding clinical management decisions.
Q7: What structural changes occur in the pulmonary vasculature during pulmonary arterial hypertension?
PAH involves multiple vascular structural changes: pulmonary vascular remodeling alters vessel architecture, sustained vasoconstriction narrows blood vessels, in situ thrombosis causes clotting within vessels, and vascular wall stiffening reduces elasticity. These combined changes increase pulmonary arterial pressure and vascular resistance, progressively impairing lung blood flow.